首页 > 最新文献

REC Interventional Cardiology最新文献

英文 中文
[[Infectious endocarditis on percutaneous aortic valve prosthesis: comparison with surgical bioprostheses]]. 经皮主动脉瓣置换术并发感染性心内膜炎与外科生物置换术的比较。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2025-01-02 eCollection Date: 2025-04-01 DOI: 10.24875/RECIC.M24000492
Lucas Barreiro, Álvaro Roldán, Nerea Aguayo, Cristina Urbano, Manuel Crespín, José López, Rafael González, Juan Carlos Castillo, Dolores Mesa, Martín Ruiz, Jorge Perea, Ignacio Gallo, Javier Suárez de Lezo, Soledad Ojeda, Manuel Pan, Manuel Anguita

Introduction and objectives: Infective endocarditis (IE) is a rare but serious complication in patients with aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). The spread of this technique to lower risk patients means that this complication may increase. The objective of this study was to analyze the incidence and mortality of IE in TAVI patients vs patients undergoing surgical aortic valve replacement (SAVR).

Methods: We conducted an observational, single-center, retrospective cohort study that included all cases of IE diagnosed consecutively in a Spanish reference center from 2008 through 2022 in patients with TAVI vs SAVR.

Results: The study included a total of 10 cases of IE in 778 patients treated with TAVI, with an incidence rate of 0.09/100 patients/year vs an incidence rate of 0.12/100 patients/year in surgical bioprostheses with 24 cases in 1457 patients (P = .64) (median follow-up of 49 months (p25-p75: 29-108). Clinical features were very similar, with 50% of TAVI patients having cardiac complications vs 33% of SAVR patients (P = .33). Although 40% of the patients from the TAVI group had a surgical indication for IE and 50% for SAVR, P = .49), only half of them underwent surgery in both groups (20% TAVI vs 25% SAVR; P = .93). No differences were reported in the 1-year mortality rate (30% TAVI vs 29% SAVR; P = .56).

Conclusions: The incidence rate of IE in this long series of TAVI patients was low and despite the worse clinical profile of TAVI patients, no significant mortality differences were found compared with the group of patients with surgical bioprosthesis.

简介和目的:感染性心内膜炎(IE)是主动脉瓣狭窄患者经导管主动脉瓣植入术(TAVI)中一种罕见但严重的并发症。这种技术在低风险患者中的推广意味着这种并发症可能会增加。本研究的目的是分析TAVI患者与手术主动脉瓣置换术(SAVR)患者的IE发病率和死亡率。方法:我们进行了一项观察性、单中心、回顾性队列研究,纳入了2008年至2022年在西班牙参考中心连续诊断的TAVI与SAVR患者中所有IE病例。结果:本研究纳入778例TAVI患者中IE发生率为10例,发生率为0.09/100例/年,而1457例外科生物假体患者中IE发生率为0.12/100例/年(P = 0.64)(中位随访时间为49个月(p25-p75: 29-108)。临床特征非常相似,50%的TAVI患者有心脏并发症,33%的SAVR患者有心脏并发症(P = 0.33)。尽管TAVI组中40%的患者有IE的手术指征,50%的患者有SAVR的手术指征,P = 0.49),但两组中只有一半的患者接受了手术(TAVI组20% vs SAVR组25%;P = .93)。1年死亡率(TAVI为30% vs SAVR为29%;P = .56)。结论:在这一长串TAVI患者中IE的发生率较低,尽管TAVI患者的临床状况较差,但与外科生物假体患者组相比,死亡率无显著差异。
{"title":"[[Infectious endocarditis on percutaneous aortic valve prosthesis: comparison with surgical bioprostheses]].","authors":"Lucas Barreiro, Álvaro Roldán, Nerea Aguayo, Cristina Urbano, Manuel Crespín, José López, Rafael González, Juan Carlos Castillo, Dolores Mesa, Martín Ruiz, Jorge Perea, Ignacio Gallo, Javier Suárez de Lezo, Soledad Ojeda, Manuel Pan, Manuel Anguita","doi":"10.24875/RECIC.M24000492","DOIUrl":"10.24875/RECIC.M24000492","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Infective endocarditis (IE) is a rare but serious complication in patients with aortic valve stenosis undergoing transcatheter aortic valve implantation (TAVI). The spread of this technique to lower risk patients means that this complication may increase. The objective of this study was to analyze the incidence and mortality of IE in TAVI patients vs patients undergoing surgical aortic valve replacement (SAVR).</p><p><strong>Methods: </strong>We conducted an observational, single-center, retrospective cohort study that included all cases of IE diagnosed consecutively in a Spanish reference center from 2008 through 2022 in patients with TAVI vs SAVR.</p><p><strong>Results: </strong>The study included a total of 10 cases of IE in 778 patients treated with TAVI, with an incidence rate of 0.09/100 patients/year vs an incidence rate of 0.12/100 patients/year in surgical bioprostheses with 24 cases in 1457 patients (<i>P</i> = .64) (median follow-up of 49 months (p25-p75: 29-108). Clinical features were very similar, with 50% of TAVI patients having cardiac complications vs 33% of SAVR patients (<i>P</i> = .33). Although 40% of the patients from the TAVI group had a surgical indication for IE and 50% for SAVR, <i>P</i> = .49), only half of them underwent surgery in both groups (20% TAVI vs 25% SAVR; <i>P</i> = .93). No differences were reported in the 1-year mortality rate (30% TAVI vs 29% SAVR; <i>P</i> = .56).</p><p><strong>Conclusions: </strong>The incidence rate of IE in this long series of TAVI patients was low and despite the worse clinical profile of TAVI patients, no significant mortality differences were found compared with the group of patients with surgical bioprosthesis.</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"7 2","pages":"75-81"},"PeriodicalIF":1.2,"publicationDate":"2025-01-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12118561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144175157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Spain]. [西班牙射频肾去神经治疗未控制高血压的成本-效果分析]。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-30 eCollection Date: 2024-10-01 DOI: 10.24875/RECIC.M24000478
Oriol Rodríguez-Leor, Anne M Ryschon, Khoa N Cao, Fernando Jaén-Águila, Tamara García-Camarero, Carlos Mansilla-Morales, Michael Kolovetsios, María Álvarez-Orozco, José Antonio García-Donaire, Jan B Pietzsch

Introduction and objectives: Radiofrequency (RF) renal denervation (RDN) has been shown to be a safe and effective treatment option for patients with uncontrolled hypertension. This analysis sought to explore the cost-effectiveness of this therapy in Spain.

Methods: A decision-analytic Markov model projected clinical events, quality-adjusted life years (QALY) and costs over the patients' lifetime. Treatment effectiveness in the base case analysis was informed by the change in office systolic blood pressure observed in the full cohort of the SPYRAL HTN-ON MED trial (-4.9 mmHg vs sham control). Alternate scenarios were calculated for effect sizes reported in the HTN-ON MED subcohort of patients on 3 antihypertensive medications treated outside the United States, the HTN-OFF MED trial, and the Global SYMPLICITY Registry high-risk and very high-risk cohorts. The analysis was conducted from the Spanish National Health System perspective and a willingness-to-pay a threshold of 25000 per QALY gained was considered.

Results: RF RDN therapy resulted in clinical event reductions (10-year relative risk 0.80 for stroke, 0.88 for myocardial infarction, and 0.72 for heart failure) and a lifetime gain of 0.35 (13.99 vs 13.63) QALYs. Incremental lifetime costs were 5335 (26 381 vs 21 045), resulting in an incremental cost-effectiveness ratio of 15 057 per QALY gained. Cost-effectiveness was further improved among all the other clinical evidence scenarios.

Conclusions: The results of this study suggest that RF RDN can provide a cost-effective alternative in the treatment of uncontrolled hypertension in Spain.

简介和目的:射频(RF)肾去神经支配(RDN)已被证明是一种安全有效的治疗高血压患者的选择。本分析旨在探讨该疗法在西班牙的成本效益。方法:采用决策分析马尔可夫模型预测患者一生中的临床事件、质量调整生命年(QALY)和成本。基本病例分析中的治疗效果是通过在SPYRAL HTN-ON MED试验的全队列中观察到的收缩压变化(与假对照组相比-4.9 mmHg)来确定的。对在美国以外接受3种降压药物治疗的患者的HTN-ON MED亚队列、HTN-OFF MED试验和Global SYMPLICITY Registry高风险和非常高风险队列中报告的效应量进行了不同情况的计算。分析是从西班牙国家卫生系统的角度进行的,并考虑了每获得QALY 25,000的支付意愿阈值。结果:RF RDN治疗导致临床事件减少(卒中的10年相对危险度为0.80,心肌梗死的10年相对危险度为0.88,心力衰竭的10年相对危险度为0.72),终生增益为0.35 (13.99 vs 13.63) QALYs。增量生命周期成本为5335 (26381 vs 21045),每获得QALY的增量成本效益比为15057。在所有其他临床证据情景下,成本-效果进一步提高。结论:本研究的结果表明,RF RDN可以为西班牙不受控制的高血压提供一种经济有效的治疗方法。
{"title":"[Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Spain].","authors":"Oriol Rodríguez-Leor, Anne M Ryschon, Khoa N Cao, Fernando Jaén-Águila, Tamara García-Camarero, Carlos Mansilla-Morales, Michael Kolovetsios, María Álvarez-Orozco, José Antonio García-Donaire, Jan B Pietzsch","doi":"10.24875/RECIC.M24000478","DOIUrl":"10.24875/RECIC.M24000478","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Radiofrequency (RF) renal denervation (RDN) has been shown to be a safe and effective treatment option for patients with uncontrolled hypertension. This analysis sought to explore the cost-effectiveness of this therapy in Spain.</p><p><strong>Methods: </strong>A decision-analytic Markov model projected clinical events, quality-adjusted life years (QALY) and costs over the patients' lifetime. Treatment effectiveness in the base case analysis was informed by the change in office systolic blood pressure observed in the full cohort of the SPYRAL HTN-ON MED trial (-4.9 mmHg vs sham control). Alternate scenarios were calculated for effect sizes reported in the HTN-ON MED subcohort of patients on 3 antihypertensive medications treated outside the United States, the HTN-OFF MED trial, and the Global SYMPLICITY Registry high-risk and very high-risk cohorts. The analysis was conducted from the Spanish National Health System perspective and a willingness-to-pay a threshold of 25000 per QALY gained was considered.</p><p><strong>Results: </strong>RF RDN therapy resulted in clinical event reductions (10-year relative risk 0.80 for stroke, 0.88 for myocardial infarction, and 0.72 for heart failure) and a lifetime gain of 0.35 (13.99 vs 13.63) QALYs. Incremental lifetime costs were 5335 (26 381 vs 21 045), resulting in an incremental cost-effectiveness ratio of 15 057 per QALY gained. Cost-effectiveness was further improved among all the other clinical evidence scenarios.</p><p><strong>Conclusions: </strong>The results of this study suggest that RF RDN can provide a cost-effective alternative in the treatment of uncontrolled hypertension in Spain.</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"6 4","pages":"305-312"},"PeriodicalIF":1.2,"publicationDate":"2024-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143800","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The role of implant projection in optimizing transcatheter aortic valve implantation]. 【种植体投影在优化经导管主动脉瓣植入术中的作用】。
IF 1.1 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-17 eCollection Date: 2024-10-01 DOI: 10.24875/RECIC.M24000476
Rut Álvarez-Velasco, Marcel Almendárez, Alberto Alperi, Paula Antuña, Raquel Del Valle, Cesar Morís, Isaac Pascual

Severe aortic stenosis is the most frequent valve condition requiring surgery, and its incidence is increasing yearly. Transcatheter aortic valve implantation (TAVI) is the first-line treatment for patients at all levels of surgical risk. Nevertheless, modifications to the procedure often appear to improve clinical outcomes. A major concern after TAVI is the higher rate of permanent pacemaker implantation (PPMI) compared with surgical valve replacement. Optimal implantation depth is crucial to reduce the burden of PPMI without causing serious complications such as valve embolization. The classic implantation technique, where the 3 cusps are aligned in the same plane, has been modified to a cusp overlap projection by isolating the noncoronary cusp and superimposing the left and right cusps. This simple modification provides optimal visualization during deployment and helps to achieve the desired implant depth to reduce conduction disturbances and PPMI. Another limitation after TAVI is coronary reaccess due to the frame of the transcatheter valve obstructing the coronary ostia. Commissural alignment of the prostheses with the native valve may facilitate selective cannulation of the coronary arteries after this procedure. This review will discuss the techniques and supporting evidence for these modifications to the deployment and implant projection methods, and how they can improve TAVI outcomes.

严重主动脉瓣狭窄是最常见的需要手术的瓣膜疾病,其发病率逐年增加。经导管主动脉瓣植入术(TAVI)是各种手术风险患者的一线治疗方法。然而,对手术过程的修改通常会改善临床结果。与外科瓣膜置换术相比,TAVI后的一个主要问题是永久性起搏器植入(PPMI)的比例更高。最佳植入深度对于减轻PPMI的负担而不引起严重并发症(如瓣膜栓塞)至关重要。经典的植入技术,即3个尖头在同一平面上排列,通过分离非冠状动脉尖头和叠加左右尖头,已被修改为尖头重叠投影。这种简单的修改在部署过程中提供了最佳的可视化效果,并有助于实现所需的植入深度,以减少传导干扰和PPMI。TAVI后的另一个限制是冠状动脉再通路,因为经导管瓣膜的框架阻塞了冠状动脉开口。手术后,假体与原瓣膜的接合面对齐可以促进冠状动脉的选择性插管。这篇综述将讨论这些技术和支持证据的修改部署和种植体投射方法,以及它们如何改善TAVI的结果。
{"title":"[The role of implant projection in optimizing transcatheter aortic valve implantation].","authors":"Rut Álvarez-Velasco, Marcel Almendárez, Alberto Alperi, Paula Antuña, Raquel Del Valle, Cesar Morís, Isaac Pascual","doi":"10.24875/RECIC.M24000476","DOIUrl":"10.24875/RECIC.M24000476","url":null,"abstract":"<p><p>Severe aortic stenosis is the most frequent valve condition requiring surgery, and its incidence is increasing yearly. Transcatheter aortic valve implantation (TAVI) is the first-line treatment for patients at all levels of surgical risk. Nevertheless, modifications to the procedure often appear to improve clinical outcomes. A major concern after TAVI is the higher rate of permanent pacemaker implantation (PPMI) compared with surgical valve replacement. Optimal implantation depth is crucial to reduce the burden of PPMI without causing serious complications such as valve embolization. The classic implantation technique, where the 3 cusps are aligned in the same plane, has been modified to a cusp overlap projection by isolating the noncoronary cusp and superimposing the left and right cusps. This simple modification provides optimal visualization during deployment and helps to achieve the desired implant depth to reduce conduction disturbances and PPMI. Another limitation after TAVI is coronary reaccess due to the frame of the transcatheter valve obstructing the coronary ostia. Commissural alignment of the prostheses with the native valve may facilitate selective cannulation of the coronary arteries after this procedure. This review will discuss the techniques and supporting evidence for these modifications to the deployment and implant projection methods, and how they can improve TAVI outcomes.</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"6 4","pages":"332-339"},"PeriodicalIF":1.1,"publicationDate":"2024-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Debate: Preventive coronary intervention for vulnerable plaque. The interventional cardiologist's approach]. [辩论:易损斑块的预防性冠状动脉介入治疗。]介入心脏病专家的方法]。
IF 1.1 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-16 eCollection Date: 2025-01-01 DOI: 10.24875/RECIC.M24000485
Josep Gómez-Lara
{"title":"[Debate: Preventive coronary intervention for vulnerable plaque. The interventional cardiologist's approach].","authors":"Josep Gómez-Lara","doi":"10.24875/RECIC.M24000485","DOIUrl":"10.24875/RECIC.M24000485","url":null,"abstract":"","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"7 1","pages":"54-56"},"PeriodicalIF":1.1,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Debate: Preventive coronary intervention for vulnerable plaque. The clinical cardiologist's approach]. [辩论:易损斑块的预防性冠状动脉介入治疗。]临床心脏病专家的方法]。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-16 eCollection Date: 2025-01-01 DOI: 10.24875/RECIC.M24000486
Rosa Fernández-Olmo
{"title":"[Debate: Preventive coronary intervention for vulnerable plaque. The clinical cardiologist's approach].","authors":"Rosa Fernández-Olmo","doi":"10.24875/RECIC.M24000486","DOIUrl":"10.24875/RECIC.M24000486","url":null,"abstract":"","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"7 1","pages":"51-53"},"PeriodicalIF":1.2,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Management of collaterals after Glenn procedure and its impact on patients with a single ventricle: a single-center study]. [格伦手术后络的处理及其对单心室患者的影响:一项单中心研究]。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-16 eCollection Date: 2024-10-01 DOI: 10.24875/RECIC.M24000475
Yasmin Abdelrazek Ali, Nehad El-Sayed Nour El-Deen, Ghada Samir Elshahed

Introduction and objectives: The bidirectional Glenn shunt (BDG) is an essential step in the repair of a physiologically single-ventricle heart. BDG increases pulmonary blood flow, allows growth of the pulmonary arteries, and improves SaO2. The procedure also allows unloading of ventricular volume, thereby improving survival. Our aim was to register all patients who developed collaterals following BDG, document the management methods used, and assess their impact.

Methods: We included 56 patients who underwent BDG procedures at a median age of 2.08 (1-3) years. After BDG, peripheral pulmonary stenting was used in 2 patients. Symptomatic hyperviscosity was present in 10 patients (17.86%), who underwent venesection. BDG was unsuccessful in 2 patients. Venovenous collaterals were observed in 41 patients (73.2%), and aortopulmonary collaterals in 37 (66.1%).

Results: Hematocrit levels were significantly higher in patients with venovenous collaterals (50.00 ± 8.76) than in those without (P = .031). Mean pulmonary artery pressure was also significantly higher in patients with venovenous collaterals (15 [12-18] mmHg; P = .025). One patient had undergone successful closure of venovenous collaterals to epicardial veins and abdominal veins 3 years previously. Seven patients underwent transcatheter closure (TCC) of collaterals. Of these, 4 patients underwent TCC of venovenous collaterals to left and right pulmonary veins; 1 patient underwent closure of an aortopulmonary collateral; 1 patient underwent a failed attempt at venovenous collateral closure that was complicated by an ischemic stroke; and 1 patient had localized extravasation upon separation of the cable. A highly statistically significant increase in SaO2 was observed after TCC of venovenous collaterals (69.83 ± 10.91 vs 82.83 ± 9.87; P = .008).

Conclusions: TCC of collaterals is a technically demanding but effective management strategy following BDG to improve patients' SaO2 and quality of life. Awareness of possible complications and their effective management is crucial.

简介和目的:双向格伦分流术(BDG)是修复生理性单心室心脏的重要步骤。BDG增加肺血流量,促进肺动脉生长,改善SaO2。该手术还可以减少心室容积,从而提高生存率。我们的目的是登记所有在BDG后出现侧枝的患者,记录所使用的管理方法,并评估其影响。方法:我们纳入56例接受BDG手术的患者,中位年龄为2.08(1-3)岁。2例患者行肺外周支架置入术。10例患者(17.86%)行静脉切除术后出现症状性高粘稠度。2例患者BDG治疗失败。41例(73.2%)观察到静脉侧支,37例(66.1%)观察到主动脉肺侧支。结果:有静脉侧支的患者红细胞压积水平(50.00±8.76)明显高于无静脉侧支的患者(P = 0.031)。静脉侧支患者的平均肺动脉压也显著升高(15 [12-18]mmHg;P = .025)。1例患者3年前成功闭合心外膜静脉和腹腔静脉的静脉侧支。7例患者行经导管络闭合术。其中,4例患者行左、右肺静脉静脉侧支TCC;1例患者行主动脉肺动脉侧支闭合术;1例患者接受静脉静脉侧枝闭合失败,并发缺血性中风;1例患者分离后出现局部外渗。静脉-静脉侧支TCC术后SaO2升高具有高度统计学意义(69.83±10.91 vs 82.83±9.87;P = .008)。结论:经络切除是一种技术要求高但有效的治疗策略,可改善BDG患者的SaO2和生活质量。意识到可能的并发症及其有效的管理是至关重要的。
{"title":"[Management of collaterals after Glenn procedure and its impact on patients with a single ventricle: a single-center study].","authors":"Yasmin Abdelrazek Ali, Nehad El-Sayed Nour El-Deen, Ghada Samir Elshahed","doi":"10.24875/RECIC.M24000475","DOIUrl":"10.24875/RECIC.M24000475","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>The bidirectional Glenn shunt (BDG) is an essential step in the repair of a physiologically single-ventricle heart. BDG increases pulmonary blood flow, allows growth of the pulmonary arteries, and improves SaO<sub>2</sub>. The procedure also allows unloading of ventricular volume, thereby improving survival. Our aim was to register all patients who developed collaterals following BDG, document the management methods used, and assess their impact.</p><p><strong>Methods: </strong>We included 56 patients who underwent BDG procedures at a median age of 2.08 (1-3) years. After BDG, peripheral pulmonary stenting was used in 2 patients. Symptomatic hyperviscosity was present in 10 patients (17.86%), who underwent venesection. BDG was unsuccessful in 2 patients. Venovenous collaterals were observed in 41 patients (73.2%), and aortopulmonary collaterals in 37 (66.1%).</p><p><strong>Results: </strong>Hematocrit levels were significantly higher in patients with venovenous collaterals (50.00 ± 8.76) than in those without (<i>P</i> = .031). Mean pulmonary artery pressure was also significantly higher in patients with venovenous collaterals (15 [12-18] mmHg; <i>P</i> = .025). One patient had undergone successful closure of venovenous collaterals to epicardial veins and abdominal veins 3 years previously. Seven patients underwent transcatheter closure (TCC) of collaterals. Of these, 4 patients underwent TCC of venovenous collaterals to left and right pulmonary veins; 1 patient underwent closure of an aortopulmonary collateral; 1 patient underwent a failed attempt at venovenous collateral closure that was complicated by an ischemic stroke; and 1 patient had localized extravasation upon separation of the cable. A highly statistically significant increase in SaO<sub>2</sub> was observed after TCC of venovenous collaterals (69.83 ± 10.91 vs 82.83 ± 9.87; <i>P</i> = .008).</p><p><strong>Conclusions: </strong>TCC of collaterals is a technically demanding but effective management strategy following BDG to improve patients' SaO<sub>2</sub> and quality of life. Awareness of possible complications and their effective management is crucial.</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"6 4","pages":"296-304"},"PeriodicalIF":1.2,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097323/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Distal radial access for coronary procedures in an all-comer population: the first 1000 patients in a prospective cohort]. [在所有患者中桡动脉远端进入冠状动脉手术:前瞻性队列中的前1000例患者]。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-15 eCollection Date: 2024-10-01 DOI: 10.24875/RECIC.M24000473
Kristian Rivera, Diego Fernández-Rodríguez, Marcos García-Guimarães, Juan Casanova-Sandoval, Patricia Irigaray, Marta Zielonka, Tania Ramírez Martínez, David Arroyo-Calpe, Joan Costa-Mateu, María Tornel-Cerezo, Anna Baiget-Pons, Oriol Roig-Boira, Eduard Perelló-Cortí, Xenia Castillo-Peña, Raquel Royo-Beltrán, Fernando Worner, José Luis Ferreiro

Introduction and objectives: Distal radial access (DRA) for coronary procedures is currently recognized as an alternative to conventional transradial access, with documented advantages primarily related to access-related complications. However, widespread adoption of DRA as the default approach remains limited. Therefore, this prospective cohort study aimed to present our initial experience with DRA for coronary procedures in any clinical settings.

Methods: From August 2020 to November 2023, we included 1000 DRA procedures (943 patients) conducted at a single center. The study enrolled a diverse patient population. We recommended pre- and postprocedural ultrasound evaluations of the radial artery course, with ultrasound-guided DRA puncture. The primary endpoint was DRA success, while secondary endpoints included coronary procedure success, DRA performance metrics, and the incidence of access-related complications.

Results: The DRA success rate was 97.4% (n = 974), with coronary procedure success at 96.9% (n = 969). The median DRA time was 40 [interquartile range, 30-60] seconds. Diagnostic procedures accounted for 64% (n = 644) of cases, while 36% (n = 356) involved percutaneous coronary intervention (PCI), including primary PCI in 13% (n = 128). Pre-procedure ultrasound evaluation and ultrasound-guided DRA were performed in 83% (n = 830) and 85% (n = 848) of cases, respectively. Access-related complications occurred in 2.9% (n = 29).

Conclusions: This study shows the safety and feasibility of DRA for coronary procedures, particularly when performed under ultrasound guidance in a diverse patient population. High rates of successful access and coronary procedure outcomes were observed, together with a low incidence of access-related complications. The study was registered on ClinicalTrials.gov (NTC06165406).

简介和目的:桡动脉远端通路(DRA)目前被认为是传统经桡动脉通路的替代方案,其优势主要与通路相关的并发症有关。然而,将DRA作为默认方法的广泛采用仍然有限。因此,这项前瞻性队列研究旨在介绍我们在任何临床环境中冠状动脉手术中DRA的初步经验。方法:从2020年8月到2023年11月,我们纳入了在单个中心进行的1000例DRA手术(943例患者)。该研究招募了不同的患者群体。我们建议术前和术后对桡动脉进行超声评估,并在超声引导下进行DRA穿刺。主要终点是DRA成功,次要终点包括冠状动脉手术成功、DRA性能指标和通路相关并发症的发生率。结果:DRA成功率为97.4% (n = 974),冠状动脉手术成功率为96.9% (n = 969)。中位DRA时间为40秒[四分位数间距,30-60]秒。诊断程序占64% (n = 644)的病例,而36% (n = 356)涉及经皮冠状动脉介入治疗(PCI),包括13% (n = 128)的原发性PCI。术前超声评估和超声引导下DRA分别占83% (n = 830)和85% (n = 848)的病例。通路相关并发症发生率为2.9% (n = 29)。结论:本研究显示了DRA在冠状动脉手术中的安全性和可行性,特别是在不同患者人群中超声引导下进行时。观察到高通道成功率和冠状动脉手术结果,以及低通道相关并发症的发生率。该研究已在ClinicalTrials.gov注册(NTC06165406)。
{"title":"[Distal radial access for coronary procedures in an all-comer population: the first 1000 patients in a prospective cohort].","authors":"Kristian Rivera, Diego Fernández-Rodríguez, Marcos García-Guimarães, Juan Casanova-Sandoval, Patricia Irigaray, Marta Zielonka, Tania Ramírez Martínez, David Arroyo-Calpe, Joan Costa-Mateu, María Tornel-Cerezo, Anna Baiget-Pons, Oriol Roig-Boira, Eduard Perelló-Cortí, Xenia Castillo-Peña, Raquel Royo-Beltrán, Fernando Worner, José Luis Ferreiro","doi":"10.24875/RECIC.M24000473","DOIUrl":"10.24875/RECIC.M24000473","url":null,"abstract":"<p><strong>Introduction and objectives: </strong>Distal radial access (DRA) for coronary procedures is currently recognized as an alternative to conventional transradial access, with documented advantages primarily related to access-related complications. However, widespread adoption of DRA as the default approach remains limited. Therefore, this prospective cohort study aimed to present our initial experience with DRA for coronary procedures in any clinical settings.</p><p><strong>Methods: </strong>From August 2020 to November 2023, we included 1000 DRA procedures (943 patients) conducted at a single center. The study enrolled a diverse patient population. We recommended pre- and postprocedural ultrasound evaluations of the radial artery course, with ultrasound-guided DRA puncture. The primary endpoint was DRA success, while secondary endpoints included coronary procedure success, DRA performance metrics, and the incidence of access-related complications.</p><p><strong>Results: </strong>The DRA success rate was 97.4% (n = 974), with coronary procedure success at 96.9% (n = 969). The median DRA time was 40 [interquartile range, 30-60] seconds. Diagnostic procedures accounted for 64% (n = 644) of cases, while 36% (n = 356) involved percutaneous coronary intervention (PCI), including primary PCI in 13% (n = 128). Pre-procedure ultrasound evaluation and ultrasound-guided DRA were performed in 83% (n = 830) and 85% (n = 848) of cases, respectively. Access-related complications occurred in 2.9% (n = 29).</p><p><strong>Conclusions: </strong>This study shows the safety and feasibility of DRA for coronary procedures, particularly when performed under ultrasound guidance in a diverse patient population. High rates of successful access and coronary procedure outcomes were observed, together with a low incidence of access-related complications. The study was registered on ClinicalTrials.gov (NTC06165406).</p>","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"6 4","pages":"287-295"},"PeriodicalIF":1.2,"publicationDate":"2024-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[REC: Interventional Cardiology goes from strength to strength]. [REC:介入心脏病学越来越强大]。
IF 1.1 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-09 eCollection Date: 2024-10-01 DOI: 10.24875/RECIC.M24000481
José M de la Torre-Hernández, Fernando Alfonso, Raúl Moreno, Soledad Ojeda, Armando Pérez de Prado, Rafael Romaguera
{"title":"[REC: Interventional Cardiology goes from strength to strength].","authors":"José M de la Torre-Hernández, Fernando Alfonso, Raúl Moreno, Soledad Ojeda, Armando Pérez de Prado, Rafael Romaguera","doi":"10.24875/RECIC.M24000481","DOIUrl":"10.24875/RECIC.M24000481","url":null,"abstract":"","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"6 4","pages":"259-265"},"PeriodicalIF":1.1,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Correction in article by Freixa-Benavente et al. "Cardiac catheterization activity in pediatric cardiac transplantation. Can catheterization needs be predicted?", REC Interv Cardiol. 2024;6:97-105]. [Freixa-Benavente等人对文章的更正。]儿童心脏移植的心导管插入术活动。导管需求能否预测? [j].中华心内科杂志。2024;6:97-105。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-20 eCollection Date: 2024-10-01 DOI: 10.24875/RECIC.M24000482
{"title":"[Correction in article by Freixa-Benavente et al. \"Cardiac catheterization activity in pediatric cardiac transplantation. Can catheterization needs be predicted?\", REC Interv Cardiol. 2024;6:97-105].","authors":"","doi":"10.24875/RECIC.M24000482","DOIUrl":"https://doi.org/10.24875/RECIC.M24000482","url":null,"abstract":"","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"6 4","pages":"363"},"PeriodicalIF":1.2,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12097383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Debate: ECMO in patients with cardiogenic shock due to myocardial infarction. A researcher's perspective]. [辩论:ECMO在心肌梗死性心源性休克患者中的应用。]一个研究人员的观点]。
IF 1.2 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-08-15 eCollection Date: 2024-10-01 DOI: 10.24875/RECIC.M24000474
Holger Thiele
{"title":"[Debate: ECMO in patients with cardiogenic shock due to myocardial infarction. A researcher's perspective].","authors":"Holger Thiele","doi":"10.24875/RECIC.M24000474","DOIUrl":"10.24875/RECIC.M24000474","url":null,"abstract":"","PeriodicalId":34295,"journal":{"name":"REC Interventional Cardiology","volume":"6 4","pages":"340-342"},"PeriodicalIF":1.2,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12120490/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144180182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
REC Interventional Cardiology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1